New research suggests that the type of fat people eat may matter more than the amount when it comes to cancer risk. The study focuses on Pancreatic ductal adenocarcinoma, one of the most aggressive cancers. In experiments using mice with the same calorie intake, different fats had very different effects. Oleic acid, a monounsaturated fat […]
Fat Type, Not Amount, Drives Pancreatic ductal adenocarcinoma Risk Read More »
In the study of 55 patients, the drug achieved a major response rate of 61.8% and an overall response rate of 83.6%, with disease control in 98.2% of patients. Responses were durable, with a median duration of 17.8 months and median progression-free survival of 13.5 months. The treatment also performed well in high-risk patients, including
At Digestive Disease Week 2026, Alpha Tau Medical reported strong early results from two first-in-human trials of Alpha DaRT® (Diffusing Alpha-emitters Radiation Therapy) in pancreatic cancer. In 19 evaluable patients with advanced, heavily pretreated pancreatic adenocarcinoma, the treatment achieved 100% local disease control. Most patients (79%) had stable disease, and 21% showed tumor shrinkage. Side
Alpha DaRT Radiation Therapy Shows 100% Local Control in Early Pancreatic Cancer Trials Read More »
Doctors have performed a world-first genetic immunotherapy treatment for pancreatic cancer, adapting immune cell techniques usually used in blood cancers to treat a solid tumor. The process involves removing a patient’s T-cells, genetically modifying them to recognize specific features of pancreatic cancer cells, and then reinfusing them back into the body so they can target and
World-First Genetic Immunotherapy Trial Targets Pancreatic Cancer Read More »
Updated results from the Phase 1 REO 022 trial show that pelareorep (Reolysin), an oncolytic virus, added to standard FOLFIRI and bevacizumab may significantly improve outcomes in RAS-mutant, microsatellite-stable metastatic colorectal cancer. The combination performed much better than historical results for second-line treatment. Median duration of response reached 19.5 months compared with about 4 to
The Phase 2 CAR-PRISM trial shows striking results for high-risk smoldering multiple myeloma using the CAR T-cell therapy ciltacabtagene autoleucel (Carvykti). A single infusion led to 100% of patients achieving minimal residual disease (MRD) negativity at a very deep level. At a median follow-up of 15.3 months, all patients achieved complete or stringent complete responses, with
Early clinical data suggest that ozekibart (INBRX-109), a DR5 agonist, could offer a new treatment option for Ewing sarcoma, a rare and aggressive cancer. In a Phase 1 study, ozekibart was combined with standard chemotherapy (temozolomide and irinotecan) in patients with relapsed or refractory disease. Among 31 patients, the response rate reached 64.5%, much higher
Ozekibart Shows Promising Response Rates in Relapsed Ewing Sarcoma Read More »
Updated results from the Phase 1 REO 022 trial show that pelareorep (Reolysin), an oncolytic virus, combined with bevacizumab and FOLFIRI, may significantly improve outcomes in KRAS-mutant metastatic colorectal cancer. Patients receiving the combination had a response rate of 33% and a median duration of response of 19.5 months, far better than typical results with
On May 1, 2026, the FDA approved vepdegestrant (Veppanu) for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. At the same time, the Guardant360 CDx was approved as a companion diagnostic to detect these mutations using a simple blood test. The approval is based on the Phase 3 VERITAC-2 trial, which compared vepdegestrant
FDA Approves Vepdegestrant with Liquid Biopsy Test for ESR1-Mutated Breast Cancer Read More »
The Phase 2 PRIMO trial found that duvelisib (Copiktra), an oral drug targeting PI3K-δ and PI3K-γ, can work as a single treatment for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). In the study of 123 heavily pretreated patients, nearly half responded to the drug. The overall response rate was 48%, with about one-third
Duvelisib Shows Strong Activity in Relapsed Peripheral T-Cell Lymphoma Read More »